This paper provides an update on the international dialogue on methodology used in drug development and regulatory review from a regulatory perspective. Factors responsible for the dramatic increase in the dialogue in recent years are explained. American guidelines and initiatives to improve methodological approaches to drug development and drug evaluation, and two specific statistical approaches to current problems, are covered.
Ethnic Factors in the Acceptability of Foreign Data.International Conference on Harmonization (ICH); E5 Efficacy Expert Working Group; Draft. 1994:1–15.
2.
International Conference on Harmonization (ICH) Expert Working Group. Draft Tripartite Guideline, The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions; Released for Comment at the Step 2 of the ICH Process; 1-3. October 1993.
3.
Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Applications; Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services.1988.
4.
IngelfingerJAMostellerFThibodeauLAWareJH. Biostatistics in Clinical Medicine. Second Edition. New York: MacMillan, Inc.; 1987.
5.
GailM.Power Computations for Designing Comparative Poisson Trials. Biometrics.1974;30:231–237.
6.
SylvesterRJQuality of Institutional Participation in Multicenter Clinical Trials. New Eng J Med.1981:305(15);852–855.
7.
The SAMM Guidelines, United Kingdom Guidelines for Company Sponsored Safety Assessment of Marketed Medicines. Pharmacoepidem Drug Safety.1994;3:106.
8.
CastleWSerevent Nationwide Surveillance Study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J.1993;306:1034–1037.
